233 related articles for article (PubMed ID: 33977908)
21. Multidrug-resistant tuberculosis in Norway: a nationwide study, 1995-2014.
Jensenius M; Winje BA; Blomberg B; Mengshoel AT; Lippe Bv; Hannula R; Bruun JN; Knudsen PK; Rønning JO; Heldal E; Dyrhol-Riise AM
Int J Tuberc Lung Dis; 2016 Jun; 20(6):786-92. PubMed ID: 27155182
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand.
Roongruangpitayakul C; Chuchottaworn C
J Med Assoc Thai; 2013 Oct; 96(10):1273-82. PubMed ID: 24350407
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment.
Jeong BH; Jeon K; Park HY; Kwon OJ; Lee KS; Kim HK; Choi YS; Kim J; Huh HJ; Lee NY; Koh WJ
J Antimicrob Chemother; 2015 Nov; 70(11):3127-33. PubMed ID: 26203184
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study.
Guglielmetti L; Veziris N; Aubry A; Brossier F; Bernard C; Sougakoff W; Jarlier V; Robert J
Int J Tuberc Lung Dis; 2018 Jan; 22(1):54-59. PubMed ID: 29297426
[TBL] [Abstract][Full Text] [Related]
26. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Tiberi S; Sotgiu G; D'Ambrosio L; Centis R; Abdo Arbex M; Alarcon Arrascue E; Alffenaar JW; Caminero JA; Gaga M; Gualano G; Skrahina A; Solovic I; Sulis G; Tadolini M; Alarcon Guizado V; De Lorenzo S; Roby Arias AJ; Scardigli A; Akkerman OW; Aleksa A; Artsukevich J; Auchynka V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Payen MC; Piana A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2016 Jun; 47(6):1758-66. PubMed ID: 27076583
[TBL] [Abstract][Full Text] [Related]
27. Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference?
Balabanova Y; Ignatyeva O; Fiebig L; Riekstina V; Danilovits M; Jaama K; Davidaviciene E; Radiulyte B; Popa CM; Nikolayevskyy V; Drobniewski F
Thorax; 2016 Sep; 71(9):854-61. PubMed ID: 27012887
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: A five-year review.
Pang Y; Lu J; Huo F; Ma Y; Zhao L; Li Y; Liang Q; Chu N; Gao M; Huang H
J Infect; 2017 Nov; 75(5):433-440. PubMed ID: 28804028
[TBL] [Abstract][Full Text] [Related]
29. Laboratory-Based Surveillance of Extensively Drug-Resistant Tuberculosis in Eastern China.
Huang Y; Wu Q; Xu S; Zhong J; Chen S; Xu J; Zhu L; He H; Wang X
Microb Drug Resist; 2017 Mar; 23(2):236-240. PubMed ID: 27754791
[TBL] [Abstract][Full Text] [Related]
30. Drug Resistance Characteristics of
Wu X; Yang J; Tan G; Liu H; Liu Y; Guo Y; Gao R; Wan B; Yu F
Front Cell Infect Microbiol; 2019; 9():345. PubMed ID: 31828045
[No Abstract] [Full Text] [Related]
31. High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.
Niehaus AJ; Mlisana K; Gandhi NR; Mathema B; Brust JC
PLoS One; 2015; 10(9):e0135003. PubMed ID: 26332235
[TBL] [Abstract][Full Text] [Related]
32. First series of patients with XDR and pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina.
Palmero D; González Montaner P; Cufré M; García A; Vescovo M; Poggi S
Arch Bronconeumol; 2015 Oct; 51(10):e49-52. PubMed ID: 26026689
[TBL] [Abstract][Full Text] [Related]
33. Trends in drug-resistant tuberculosis in China: data from a clinical tuberculosis centre.
Liao S; Cai C; Huo FM; Wu JN; Kong CC; Huang HR; Xu SF; Sun ZG
Int J Tuberc Lung Dis; 2017 Sep; 21(9):990-995. PubMed ID: 28826447
[TBL] [Abstract][Full Text] [Related]
34. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.
Velayati AA; Masjedi MR; Farnia P; Tabarsi P; Ghanavi J; ZiaZarifi AH; Hoffner SE
Chest; 2009 Aug; 136(2):420-425. PubMed ID: 19349380
[TBL] [Abstract][Full Text] [Related]
35. Extensively drug-resistant tuberculosis in california, 1993-2006.
Banerjee R; Allen J; Westenhouse J; Oh P; Elms W; Desmond E; Nitta A; Royce S; Flood J
Clin Infect Dis; 2008 Aug; 47(4):450-7. PubMed ID: 18616396
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan.
Makhmudova M; Maxsumova Z; Rajabzoda A; Makhmadov A; van den Hof S; Mirtskhulava V
Int J Tuberc Lung Dis; 2019 Mar; 23(3):331-336. PubMed ID: 30871664
[TBL] [Abstract][Full Text] [Related]
37. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
Centers for Disease Control and Prevention (CDC)
MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
[TBL] [Abstract][Full Text] [Related]
38. The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia.
Shibabaw A; Gelaw B; Gebreyes W; Robinson R; Wang SH; Tessema B
PLoS One; 2020; 15(2):e0229040. PubMed ID: 32053661
[TBL] [Abstract][Full Text] [Related]
39. Redefining MDR-TB: Comparison of Mycobacterium tuberculosis clinical isolates from Russia and Taiwan.
Jou R; Lee WT; Kulagina EV; Weng JY; Isakova AI; Lin WH; Antonova OV; Wu MH; Arslanbaeva LR; Tasi HY; Nosova EY; Zimenkov DV
Infect Genet Evol; 2019 Aug; 72():141-146. PubMed ID: 30593924
[TBL] [Abstract][Full Text] [Related]
40. [Investigation of extensive drug resistance in multidrug resistance tuberculosis isolates].
Bektöre B; Haznedaroğlu T; Baylan O; Ozyurt M; Ozkütük N; Satana D; Cavuşoğlu C; Seber E
Mikrobiyol Bul; 2013 Jan; 47(1):59-70. PubMed ID: 23390903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
